Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
Open Access
- 1 May 2016
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 74 (5) , 841-850
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Systemic Therapy for Psoriasis and the Risk of Herpes ZosterJAMA Dermatology, 2015
- Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis surveyJournal of the European Academy of Dermatology and Venereology, 2015
- Current and Future Oral Systemic Therapies for PsoriasisDermatologic Clinics, 2015
- Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trialBritish Journal of Dermatology, 2014
- Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United StatesJAMA Dermatology, 2013
- A 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with PsoriasisNew England Journal of Medicine, 2011
- Definition of treatment goals for moderate to severe psoriasis: a European consensusArchives of Dermatological Research, 2010
- British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatologyBritish Journal of Dermatology, 2010
- Are patients with psoriasis undertreated? Results of National Psoriasis Foundation surveyJournal of the American Academy of Dermatology, 2007
- The Efficacy of Calcipotriol + Acitretin Combination Therapy for PsoriasisAmerican Journal of Clinical Dermatology, 2003